Back to Oncology
OncologyvCTCAE v5.0Evidence-Based

Immune-Related Adverse Events for GI Toxicity - Hepatitis

Grades severity of hepatitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates liver function tests including AST, ALT, and total bilirubin levels to determine the severity of immune-mediated hepatitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, hepatology consultation needs, and monitoring for life-threatening complications. ICPi-induced hepatitis has an incidence of 5-10% in single-agent therapy but severe toxicity occurs in less than 2% of cases. The calculator provides evidence-based management recommendations essential for oncologists, hepatologists, and multidisciplinary teams managing patients on immunotherapy.

Clinical Input Parameters

U/L
Range: 5 — 5000 U/L
U/L
Range: 20 — 80 U/L
U/L
Range: 5 — 5000 U/L
U/L
Range: 20 — 80 U/L
mg/dL
Range: 0.1 — 50 mg/dL
mg/dL
Range: 0.8 — 2 mg/dL
Clinical Assessment
Awaiting Parameters
grade
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Immune-Related Adverse Events for GI Toxicity - Hepatitis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

CTCAE grading based on AST/ALT fold increase over ULN and total bilirubin fold increase over ULN: Grade 1: AST/ALT 1-3× ULN OR bilirubin 1-1.5× ULN; Grade 2: AST/ALT 3-5× ULN OR bilirubin 1.5-3× ULN; Grade 3: AST/ALT 5-20× ULN OR bilirubin 3-10× ULN; Grade 4: AST/ALT >20× ULN OR bilirubin >10× ULN OR hepatic decompensation

Clinical Pearls & Practice Notes

  • Hepatic irAEs have an incidence of 5-10% in single-agent ICI therapy with severe toxicity in <2% of cases
  • All patients should undergo baseline liver chemistry evaluation before ICI therapy initiation
  • Liver chemistries should be repeated before each ICI treatment cycle
  • Consider alternative etiologies: viral hepatitis, drug-induced liver injury, autoimmune hepatitis, alcohol
  • Hepatitis pattern analysis: R value = (ALT/ULN)/(ALP/ULN) - hepatocellular (R≥5), mixed (2<R<5), cholestatic (R≤2)
  • Liver biopsy should be considered when diagnosis is unclear or for refractory cases
  • Permanent ICPi discontinuation is recommended for Grade 3-4 hepatitis
  • Corticosteroids are first-line treatment for Grade 2-4 hepatitis
  • Mycophenolate mofetil may be needed for steroid-refractory cases
  • Monitor for hepatic decompensation in severe cases - ascites, encephalopathy, coagulopathy

Evidence & Literature Citations

  1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.
  2. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.
  3. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
  4. De Martin E, Michot JM, Papoular B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033.

Score Interpretation Ranges

Grade 11 – 1 pts

Mild - AST/ALT 1-3× ULN OR total bilirubin 1-1.5× ULN

Grade 22 – 2 pts

Moderate - AST/ALT 3-5× ULN OR total bilirubin 1.5-3× ULN

Grade 33 – 3 pts

Severe - AST/ALT 5-20× ULN OR total bilirubin 3-10× ULN

Grade 44 – 4 pts

Life-threatening - AST/ALT >20× ULN OR total bilirubin >10× ULN OR hepatic decompensation

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.